SGLT2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis.

Hong-Da ZhangLei DingLi-Jie MiAi-Kai ZhangKuo ZhangZi-Han JiangFeng-Yuan YuXin-Xin YanYu-Jing ShenMin Tang

Published in: European journal of preventive cardiology (2023)

For patients with cardiometabolic diseases or risk factors, SGLT2 inhibitors did not decrease the risk of AF occurrence, regardless of follow-up duration, type or dose of the drug, or the patient population.

Keyphrases

atrial fibrillation
risk factors
risk assessment
case report
catheter ablation
left atrial
oral anticoagulants
heart failure
left atrial appendage
direct oral anticoagulants
percutaneous coronary intervention
emergency department
drug induced
venous thromboembolism
adverse drug